PE Biosystems/Third Wave Technologies
This article was originally published in The Gray Sheet
Executive Summary
Termination of a January acquisition pact under which PE Biosystems would have acquired the Madison, Wisconsin-based developer of nucleic acid technologies for stock valued in the $300 mil. range will not prevent the firms from continuing to pursue joint collaborations, including several active projects, PE says (1"The Gray Sheet" Jan. 31, p. 19). "Recent discussions...led both companies to conclude that their collective interests would be best served if the companies remain independent but continue to collaborate," PE says in a May 25 release
You may also be interested in...
Third Wave Technologies IPO Will Fund Diagnostic Genotyping Tests
Third Wave Technologies intends to develop clinical diagnostic tests for several inherited and infectious diseases, the firm said in its July 31 prospectus detailing a $100 mil. initial public offering.
Third Wave Technologies IPO Will Fund Diagnostic Genotyping Tests
Third Wave Technologies intends to develop clinical diagnostic tests for several inherited and infectious diseases, the firm said in its July 31 prospectus detailing a $100 mil. initial public offering.
Third Wave Acquisition To Drive PE Biosystems Revenue Growth In FY 2000
PE Biosystems Group's acquisition of Third Wave Technologies, announced Jan. 24, should help the company reach its top-line growth target in fiscal 2000, the firm maintained at a Jan. 27 teleconference reporting results for the second quarter ended Dec. 31.